Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test - PubMed (original) (raw)

Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test

J D Ragland et al. Psychiatry Res. 1996.

Abstract

The Paired Associate Recognition Test (PART) was developed to measure declarative memory using Wisconsin Card Sorting Test (WCST) stimuli, so that both tasks could be administered during functional neuroimaging to differentiate memory and executive function, and associated frontal and temporal lobe activation in schizophrenia. The current study was designed to compare PART and WCST performance in schizophrenic patients and to examine effects of medication and symptomatology. The PART, WCST, and standard declarative memory tasks were administered to 30 chronic schizophrenic patients and 30 matched healthy control subjects. Supporting task validity was the finding that patients were equally impaired on the PART and the WCST. Neuroleptics did not appear to affect performance. The effect of anticholinergic medication correlated negatively with WCST performance in a small subsample. Severity of schizophrenia-specific symptoms measured at intake on the Brief Psychiatric Rating Scale correlated negatively with performance on the WCST. These results support the application of the PART and WCST in future functional neuroimaging studies.

PubMed Disclaimer

Figures

Fig. 1

Mean (± SE) performance of normal control subjects (gray bar) and schizophrenic patients (striped bar) on Paired Associate Recognition Test total correct (PARTOT), Wisconsin Card Sorting Test number of categories (WCSTCAT), and Wisconsin Card Sorting Test number of perseverative errors (WCSTPE). Significance levels of group differences are indicated by asterisks: **P < 0.0001; *P < 0.05.

Cited by

Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia.
Molina V, Reig S, Desco M, Gispert JD, Sanz J, Sarramea F, Pascau J, Benito C, Martínez-Lázaro R, Luque R, Aragües M, Misiego JM, Corral IL, Palomo T. Molina V, et al. Neurotox Res. 2002 Aug-Sep;4(5-6):437-451. doi: 10.1080/10298420290031397. Neurotox Res. 2002. PMID: 12754158
Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.
Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Ventura J, et al. Schizophr Res. 2009 Sep;113(2-3):189-99. doi: 10.1016/j.schres.2009.03.035. Epub 2009 Jul 22. Schizophr Res. 2009. PMID: 19628375 Free PMC article.
Cognitive training in schizophrenia: a neuroscience-based approach.
Genevsky A, Garrett CT, Alexander PP, Vinogradov S. Genevsky A, et al. Dialogues Clin Neurosci. 2010;12(3):416-21. doi: 10.31887/DCNS.2010.12.3/agenevsky. Dialogues Clin Neurosci. 2010. PMID: 20954435 Free PMC article. Review.
A Correlative Classification Study of Schizophrenic Patients with Results of Clinical Evaluation and Structural Magnetic Resonance Images.
Chu WL, Huang MW, Jian BL, Hsu CY, Cheng KS. Chu WL, et al. Behav Neurol. 2016;2016:7849526. doi: 10.1155/2016/7849526. Epub 2016 Oct 24. Behav Neurol. 2016. PMID: 27843197 Free PMC article.
Cognitive training for impaired neural systems in neuropsychiatric illness.
Vinogradov S, Fisher M, de Villers-Sidani E. Vinogradov S, et al. Neuropsychopharmacology. 2012 Jan;37(1):43-76. doi: 10.1038/npp.2011.251. Epub 2011 Nov 2. Neuropsychopharmacology. 2012. PMID: 22048465 Free PMC article. Review.

References

1. American Psychiatric Association . DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd rev. American Psychiatric Press; Washington, DC: 1987.
1. Anderson SW, Damasio H, Jones RD, Tranel D. Wisconsin Card Sorting performance as a measure of frontal lobe damage. J Clin Exp Neuropsychol. 1991;13:909–922. - PubMed
1. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982a;39:784–788. - PubMed
1. Andreasen NC. Negative vs. positive schizophrenia: definition and validation. Arch Gen Psychiatry. 1982b;39:789–798. - PubMed
1. Arnold SE, Lee VMY, Gur RE, Trojanowski JQ. Abnormal expression of two microtubule-associated proteins (MAP2 and MAPS) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci USA. 1992;88:10850–10854. - PMC - PubMed

Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test - PubMed (original) (raw)